• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过多能性重编程生成高增殖、年轻化的细胞毒性 T 细胞克隆,用于过继免疫治疗。

Generation of highly proliferative, rejuvenated cytotoxic T cell clones through pluripotency reprogramming for adoptive immunotherapy.

机构信息

Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan.

AIDS Research Center, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo 162-8640, Japan.

出版信息

Mol Ther. 2021 Oct 6;29(10):3027-3041. doi: 10.1016/j.ymthe.2021.05.016. Epub 2021 May 21.

DOI:10.1016/j.ymthe.2021.05.016
PMID:34023508
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8530944/
Abstract

Adoptive immunotherapy has emerged as a powerful approach to cure cancer and chronic infections. Currently, the generation of a massive number of T cells that provide long-lasting immunity is challenged by exhaustion and differentiation-associated senescence, which inevitably arise during in vitro cloning and expansion. To circumvent these problems, several studies have proposed an induced pluripotent stem cell (iPSC)-mediated rejuvenation strategy to revitalize the exhausted/senescent T cell clones. Because iPSC-derived cytotoxic T lymphocytes (iPSC-CTLs) generated via commonly used monolayer systems have unfavorable, innate-like features such as aberrant natural killer (NK) activity and limited replication potential, we modified the redifferentiation culture to generate CD8αβCD5CCR7CD45RACD56-adaptive iPSC-CTLs. The modified iPSC-CTLs exhibited early memory phenotype, including high replicative capacity and the ability to give rise to potent effector cells. In expansion culture with an optimized cytokine cocktail, iPSC-CTLs proliferated more than 10-fold in a feeder-free condition. Our redifferentiation and expansion package of early memory iPSC-CTLs could supply memory and effector T cells for both autologous and allogeneic immunotherapies.

摘要

过继免疫疗法已成为治疗癌症和慢性感染的一种强大方法。目前,大量提供长期免疫的 T 细胞的产生受到体外克隆和扩增过程中不可避免出现的耗竭和分化相关衰老的挑战。为了规避这些问题,已有多项研究提出了一种诱导多能干细胞(iPSC)介导的复兴策略,以恢复耗竭/衰老的 T 细胞克隆。由于通过常用的单层系统生成的 iPSC 来源的细胞毒性 T 淋巴细胞(iPSC-CTL)具有异常的自然杀伤(NK)活性和有限的复制潜力等固有样特征,我们修改了再分化培养以生成 CD8αβCD5CCR7CD45RACD56-适应性 iPSC-CTL。改良的 iPSC-CTL 表现出早期记忆表型,包括高复制能力和产生有效效应细胞的能力。在优化细胞因子鸡尾酒的扩增培养中,iPSC-CTL 在无饲养层条件下增殖超过 10 倍。我们的早期记忆 iPSC-CTL 的再分化和扩增方案可为自体和同种异体免疫疗法提供记忆和效应 T 细胞。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84a2/8530944/5cd0b4a0b76d/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84a2/8530944/5cd0b4a0b76d/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/84a2/8530944/5cd0b4a0b76d/fx1.jpg

相似文献

1
Generation of highly proliferative, rejuvenated cytotoxic T cell clones through pluripotency reprogramming for adoptive immunotherapy.通过多能性重编程生成高增殖、年轻化的细胞毒性 T 细胞克隆,用于过继免疫治疗。
Mol Ther. 2021 Oct 6;29(10):3027-3041. doi: 10.1016/j.ymthe.2021.05.016. Epub 2021 May 21.
2
Sustainable Antiviral Efficacy of Rejuvenated HIV-Specific Cytotoxic T Lymphocytes Generated from Induced Pluripotent Stem Cells.从诱导多能干细胞中产生的再生 HIV 特异性细胞毒性 T 淋巴细胞的抗病毒可持续性。
J Virol. 2022 Mar 23;96(6):e0221721. doi: 10.1128/jvi.02217-21. Epub 2022 Feb 2.
3
Redifferentiation of Adaptive Naïve-Like CTL from T-Cell-Derived iPSC.从T细胞来源的诱导多能干细胞重新分化出适应性幼稚样细胞毒性T淋巴细胞。
Methods Mol Biol. 2019;2048:71-75. doi: 10.1007/978-1-4939-9728-2_7.
4
Differentiating CD8αβ T Cells from TCR-Transduced iPSCs for Cancer Immunotherapy.从经TCR转导的诱导多能干细胞中分化出CD8αβ T细胞用于癌症免疫治疗。
Methods Mol Biol. 2019;2048:81-84. doi: 10.1007/978-1-4939-9728-2_9.
5
'Off-the-shelf' immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes.使用诱导多能干细胞衍生的年轻化细胞毒性T淋巴细胞进行的“现成”免疫疗法。
Exp Hematol. 2017 Mar;47:2-12. doi: 10.1016/j.exphem.2016.10.009. Epub 2016 Nov 5.
6
Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes With Stem Cell-Like Memory Features for Melanoma Immunotherapy.生成具有干细胞样记忆特征的纯高功能抗肿瘤特异性细胞毒性 T 淋巴细胞用于黑色素瘤免疫治疗。
Front Immunol. 2021 Sep 8;12:674276. doi: 10.3389/fimmu.2021.674276. eCollection 2021.
7
Generation of induced pluripotent stem cell (iPSC) from NY-ESO-I-specific cytotoxic T cells isolated from the melanoma patient with minor HLAs: The practical pilot study for the adoptive immunotherapy for melanoma using iPSC technology.从患有轻度人类白细胞抗原(HLA)的黑色素瘤患者中分离出的NY-ESO-I特异性细胞毒性T细胞诱导生成诱导多能干细胞(iPSC):使用iPSC技术进行黑色素瘤过继性免疫治疗的实际初步研究。
Exp Dermatol. 2023 Feb;32(2):126-134. doi: 10.1111/exd.14686. Epub 2022 Oct 21.
8
Cloning and expansion of antigen-specific T cells using iPS cell technology: development of "off-the-shelf" T cells for the use in allogeneic transfusion settings.利用诱导多能干细胞技术克隆和扩增抗原特异性T细胞:开发用于异体输血的“现成可用”T细胞。
Int J Hematol. 2018 Mar;107(3):271-277. doi: 10.1007/s12185-018-2399-1. Epub 2018 Jan 31.
9
Directed differentiation of induced pluripotent stem cells towards T lymphocytes.诱导多能干细胞向T淋巴细胞的定向分化。
J Vis Exp. 2012 May 14(63):e3986. doi: 10.3791/3986.
10
Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ+ T cells targeting multiple myeloma.诱导多能干细胞分化为针对多发性骨髓瘤的再生 CD8αβ+ T 细胞,该细胞特异性靶向 BCMA。
Blood. 2024 Mar 7;143(10):895-911. doi: 10.1182/blood.2023020528.

引用本文的文献

1
Culturing Potential: advances in ex vivo cell culture systems for haematopoietic cell-based regenerative therapies.培养潜力:用于基于造血细胞的再生疗法的体外细胞培养系统的进展
Regen Ther. 2025 Jul 17;30:403-414. doi: 10.1016/j.reth.2025.07.001. eCollection 2025 Dec.
2
Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups.溶瘤病毒和嵌合抗原受体T细胞基因治疗进展及治疗相关分组
Curr Issues Mol Biol. 2025 Apr 10;47(4):268. doi: 10.3390/cimb47040268.
3
Regenerative Immunotherapy for Cancer: Transcription Factor Reprogramming of Tumor-Specific T Cells.

本文引用的文献

1
Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy.增强再活化的 iPSC 衍生 T 细胞中的 TCR 稳定性可提高其在癌症免疫疗法中的应用。
Cell Stem Cell. 2018 Dec 6;23(6):850-858.e4. doi: 10.1016/j.stem.2018.10.005. Epub 2018 Nov 15.
2
Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells.转铁蛋白介导的 T 细胞激活对 CD19 特异性嵌合抗原受体 T 细胞扩增和表型的影响。
Hum Gene Ther. 2018 Oct;29(10):1167-1182. doi: 10.1089/hum.2017.237. Epub 2018 Sep 5.
3
Reprogramming human T cell function and specificity with non-viral genome targeting.
癌症的再生免疫疗法:肿瘤特异性T细胞的转录因子重编程
Cancers (Basel). 2025 Jul 2;17(13):2225. doi: 10.3390/cancers17132225.
4
From induced pluripotent stem cell (iPSC) to universal immune cells: literature review of advances in a new generation of tumor therapies.从诱导多能干细胞(iPSC)到通用免疫细胞:新一代肿瘤治疗进展的文献综述
Transl Cancer Res. 2025 Apr 30;14(4):2495-2507. doi: 10.21037/tcr-24-1087. Epub 2025 Apr 15.
5
Pluripotent stem cell-based immunotherapy: advances in translational research, cell differentiation, and gene modifications.基于多能干细胞的免疫疗法:转化研究、细胞分化和基因修饰的进展
Life Med. 2025 Jan 18;4(1):lnaf002. doi: 10.1093/lifemedi/lnaf002. eCollection 2025 Feb.
6
Adoptive Cell Therapy from the Dish: Potentiating Induced Pluripotent Stem Cells.源自培养皿的过继性细胞疗法:增强诱导多能干细胞
Transfus Med Hemother. 2024 Aug 26;52(1):27-41. doi: 10.1159/000540473. eCollection 2025 Feb.
7
Senescent T Cells: The Silent Culprit in Acute Myeloid Leukemia Progression?衰老T细胞:急性髓系白血病进展中的沉默元凶?
Int J Mol Sci. 2024 Nov 22;25(23):12550. doi: 10.3390/ijms252312550.
8
Revolutionizing Cancer Treatments through Stem Cell-Derived CAR T Cells for Immunotherapy: Opening New Horizons for the Future of Oncology.通过干细胞衍生的 CAR T 细胞进行免疫疗法彻底改变癌症治疗:为肿瘤学的未来开辟新视野。
Cells. 2024 Sep 10;13(18):1516. doi: 10.3390/cells13181516.
9
A culture method with berbamine, a plant alkaloid, enhances CAR-T cell efficacy through modulating cellular metabolism.一种利用小檗胺(一种植物生物碱)的培养方法通过调节细胞代谢来增强 CAR-T 细胞的疗效。
Commun Biol. 2024 Jun 4;7(1):685. doi: 10.1038/s42003-024-06297-0.
10
Effective and stable gene transduction in rhesus macaque iPSCs capable of T-lineage differentiation utilizing the piggyBac system.利用piggyBac系统在能够进行T细胞谱系分化的恒河猴诱导多能干细胞中实现有效且稳定的基因转导。
Regen Ther. 2024 Mar 18;27:104-111. doi: 10.1016/j.reth.2024.03.002. eCollection 2024 Dec.
利用非病毒基因组靶向技术重新编程人类 T 细胞的功能和特异性。
Nature. 2018 Jul;559(7714):405-409. doi: 10.1038/s41586-018-0326-5. Epub 2018 Jul 11.
4
Generation of TCR-Expressing Innate Lymphoid-like Helper Cells that Induce Cytotoxic T Cell-Mediated Anti-leukemic Cell Response.生成表达 TCR 的先天淋巴样辅助细胞,诱导细胞毒性 T 细胞介导的抗白血病细胞反应。
Stem Cell Reports. 2018 Jun 5;10(6):1935-1946. doi: 10.1016/j.stemcr.2018.04.025. Epub 2018 May 24.
5
Generation of Tumor Antigen-Specific iPSC-Derived Thymic Emigrants Using a 3D Thymic Culture System.利用 3D 胸腺培养系统生成肿瘤抗原特异性 iPSC 衍生的胸腺迁出细胞。
Cell Rep. 2018 Mar 20;22(12):3175-3190. doi: 10.1016/j.celrep.2018.02.087.
6
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor.CAR-T 细胞中的 IL-7 和 CCL19 的表达可改善肿瘤中的免疫细胞浸润和 CAR-T 细胞存活。
Nat Biotechnol. 2018 Apr;36(4):346-351. doi: 10.1038/nbt.4086. Epub 2018 Mar 5.
7
CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells.CRISPR 介导的 TCR 替换可产生更优的抗癌转基因 T 细胞。
Blood. 2018 Jan 18;131(3):311-322. doi: 10.1182/blood-2017-05-787598. Epub 2017 Nov 9.
8
HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells.表达HLA-E的多能干细胞可逃避自然杀伤细胞的同种异体反应和裂解。
Nat Biotechnol. 2017 Aug;35(8):765-772. doi: 10.1038/nbt.3860. Epub 2017 May 15.
9
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.利用CRISPR/Cas9将嵌合抗原受体(CAR)靶向至T细胞受体α恒定区(TRAC)基因座可增强肿瘤排斥反应。
Nature. 2017 Mar 2;543(7643):113-117. doi: 10.1038/nature21405. Epub 2017 Feb 22.
10
T memory stem cells in health and disease.健康与疾病中的T记忆干细胞。
Nat Med. 2017 Jan 6;23(1):18-27. doi: 10.1038/nm.4241.